Polymyxin B vs Daptomycin — Peptide Comparison

Polymyxin B vs Daptomycin — Peptide Comparison Polymyxin B vs Daptomycin — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Polymyxin B 1.5–2.5 mg/kg Daptomycin 4–6 mg/kg Frequency Multiple times daily Once daily Administration Intravenous infusion (primary systemic route) Intravenous infusion over 30 minutes (FDA-approved) Cycle Length 4-6 weeks Onset Speed Rapid (hours to days) Evidence Level Strong human trials (Phase 3 or FDA approved) Efficacy Fighting Resistant Infections Stopping Bacterial Toxins Wound Protection Fighting Drug-Resistant Infections Bloodstream Infections Skin Infection Treatment Technical Data Molecular Formula C₅₆H₉₈N₁₆O₁₃ (polymyxin B₁ free base) Molecular Weight 1,203.5 g/mol (free base); ~1,385 g/mol (sulfate salt) Half-Life Terminal half-life: 9-11.5 hours in patients with normal renal function; does not require renal dose adjustment (unlike colistimethate); achieves steady-state within 1-2 days with loading dose Bioavailability IV: 100% (direct administration); oral: negligible (not absorbed from GI tract — used topically in the gut for selective decontamination); inhaled: local pulmonary concentrations achieved with systemic absorption variable; topical: minimal systemic absorption CAS Number 1405-20-5 (polymyxin B sulfate) C₇₂H₁₀₁N₁₇O₂₆ 1,620.69 Da Terminal half-life: 8-9 hours in healthy adults with normal renal function; supports once-daily dosing; post-antibiotic effect: 1-6 hours against S. aureus; renal dose adjustment: CrCl <30 mL/min — extend interval to every 48 hours IV: 100% (direct administration); not orally bioavailable (degraded in GI tract); inactivated in lungs by pulmonary surfactant 103060-53-3 Protocols starting Loading dose 2.0-2.5 mg/kg (20,000-25,000 IU/kg) total body weight, infused over 1 hour Single loading dose on day 1 Day 1 loading, then maintenance International consensus loading dose for serious MDR Gram-negative infections (1 mg = 10,000 units). [3] standard Maintenance 1.25-1.5 mg/kg (12,500-15,000 IU/kg) every 12 hours, infused over 1 hour Every 12 hours 7-14 days, infection-dependent Consensus maintenance dosing; unlike colistin, polymyxin B is NOT reduced for renal impairment or dialysis. FDA label range is 15,000-25,000 units/kg/day (max 25,000 units/kg/day). [3][6] 25,000-30,000 units/kg/day divided every 4-6 hours Every 4-6 hours Infection-dependent FDA label intramuscular dosing; not generally recommended due to injection-site pain. [6] 50,000 units once daily for 3-4 days, then 50,000 units every other day Daily then every other day At least 2 weeks after CSF cultures turn negative FDA label intrathecal regimen for meningitis (adults and children >2 yr); typically given with concomitant IV polymyxin. Children <2 yr: 20,000 units/day for 3-4 days. [6] Ophthalmic 0.1-0.25% solution (10,000-25,000 units/mL), 1-3 drops every hour Every hour, lengthening interval as response allows Until infection resolves FDA label ophthalmic dosing; subconjunctival injection up to 100,000 units/day for Pseudomonas aeruginosa. [6] 4 mg/kg Once every 24 hours 7–14 days FDA-approved dose for complicated skin and skin-structure infections. Given as an IV infusion over 30 minutes or as a 2-minute IV push [1]. 6 mg/kg 2–6 weeks FDA-approved dose for Staphylococcus aureus bloodstream infection (bacteremia), including right-sided heart-valve infection [2]. advanced 8–12 mg/kg Higher doses are commonly used in practice for hard-to-treat MRSA bloodstream infections; studies report this range is generally well tolerated with monitoring of muscle enzymes (CK) [3]. Applications Treatment of life-threatening multidrug-resistant Gram-negative infections when carbapenems and other agents have failed Polymyxin B is particularly well-suited for individuals focused on treatment of life-threatening multidrug-resistant gram-negative infections when carbapenems and other agents have failed. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Salvage therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and pneumonia Polymyxin B is particularly well-suited for individuals focused on salvage therapy for carbapenem-resistant acinetobacter baumannii (crab) bloodstream infections and pneumonia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Intrathecal/intraventricular treatment of MDR Gram-negative meningitis and ventriculitis Polymyxin B is particularly well-suited for individuals focused on intrathecal/intraventricular treatment of mdr gram-negative meningitis and ventriculitis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Inhaled therapy for MDR Gram-negative ventilator-associated pneumonia (VAP) as adjunct to systemic therapy Polymyxin B is particularly well-suited for individuals focused on inhaled therapy for mdr gram-negative ventilator-associated pneumonia (vap) as adjunct to systemic therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg) Daptomycin is particularly well-suited for individuals focused on treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg) Daptomycin is particularly well-suited for individuals focused on complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible Daptomycin is particularly well-suited for individuals focused on vre bloodstream infections and endocarditis when ampicillin-based therapy is not feasible. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV trea Common Nephrotoxicity Infusion-related histamine release Neurotoxicity Skin hyperpigmentation Uncommon Neuromuscular blockade Serious Acute kidney injury requiring dialysis CPK elevation GI effects (nausea, diarrhea, vomiting) Headache and insomnia Injection site reactions Eosinophilic pneumonia Rhabdomyolysis Research Status FDA Status FDA approved for this use Safety Overview Polymyxin B carries significant nephrotoxicity risk (acute tubular necrosis) and neurotoxicity risk (peripheral neuropathy, neurological effects) requiring strict monitoring. Serum concentrations >5 mg/L associated with increased renal dysfunction; dosing adjusted for creatinine clearance to minimize accumulation. IV or intramuscular use only; intrathecal administration reserved for meningitis with careful dosing. Bacterial resistance monitoring essential as polymyxins remain reserved antibiotics. Contraindications xKnown hypersensitivity to polymyxin B or polymyxin E (colistin) xSevere pre-existing renal failure without dialysis support — nephrotoxicity may be life-threatening xConcurrent use of other nephrotoxic agents (aminoglycosides, vancomycin, amphotericin B) without renal monitoring — additive nephrotoxicity risk xMyasthenia gravis — polymyxin B can exacerbate neuromuscular blockade and precipitate respiratory failure Daptomycin is an FDA-approved antibiotic with extensive clinical safety data from Phase 2/3 trials and post-market pharmacovigilance spanning over 20 years. Key safety concerns include muscle toxicity (creatine phosphokinase elevation) occurring in 3-12% of treated patients, potentially progressing to myopathy with weakness if unmonitored. Pulmonary toxicity (eosinophilic pneumonia) is rare (<1%) but serious. Peripheral neuropathy, nausea, and injection site reactions are common but usually mild. Creatinine elevation in renal impairment is significant—dosing must be reduced in patients with eGFR <30 mL/min. CPK monitoring is essential during treatment, especially in patients on statins or with baseline elevations. xKnown hypersensitivity to daptomycin or any component of the formulation xPneumonia or any lower respiratory tract infection — daptomycin is inactivated by pulmonary surfactant (phosphatidylcholine) and will fail to treat pneumonia xConcurrent use of HMG-CoA reductase inhibitors (statins) is relatively contraindicated — consider temporary discontinuation to reduce risk of additive myotoxicity xPre-existing significant skeletal muscle disease or unexplained CPK elevation >5x ULN Decision Guide Choose Polymyxin B if... Treatment of life-threatening multidrug-resistant Gram-negative infections when carbapenems and other agents have failed Salvage therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and pneumonia Intrathecal/intraventricular treatment of MDR Gram-negative meningitis and ventriculitis Inhaled therapy for MDR Gram-negative ventilator-associated pneumonia (VAP) as adjunct to systemic therapy Choose Daptomycin if... Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg) Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg) VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment